Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Total Current Liabilities (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Total Current Liabilities for 3 consecutive years, with $82.2 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 41.18% to $82.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $82.2 million through Dec 2025, up 41.18% year-over-year, with the annual reading at $82.2 million for FY2025, 41.18% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $82.2 million at Nuvation Bio, up from $68.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $82.2 million in Q4 2025, with the low at $12.6 million in Q1 2023.
  • Average Total Current Liabilities over 3 years is $42.5 million, with a median of $51.9 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities soared 316.8% in 2024, then grew 15.41% in 2025.
  • Over 3 years, Total Current Liabilities stood at $14.0 million in 2023, then surged by 316.8% to $58.2 million in 2024, then soared by 41.18% to $82.2 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $82.2 million, $68.1 million, and $66.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.